Programming

Basic Cardiovascular Sciences 2019 Scientific Sessions

July 29–August 1, 2019
Westin Boston Waterfront | Boston, Massachusetts

Registration Information
Standard rates take effect June 26


Registration rates | IMPORTANT See update on hotel rooms
 
Abstract Submission
Abstract submission is now closed.

 


Download Abstract Categories (PDF) | Submission Rules & Guidelines (PDF)

2019 Programming

Keynote Speaker: Christine Seidman, MD, Brigham and Women’s Hospital, Boston

(Below, click on a day/date to collapse or expand):

Featured Sessions

  • Early Career Pre-Conference Session
  • HFpEF: Unraveling the Gordian Knot
  • Mechanisms of Mitochondrial Quality Control
  • Early Triggers of Heart Failure
  • Beyond Myocytes and Fibroblasts: Forgotten Cells of the Heart
  • Poster Session 1

  • Women in Science Breakfast
  • Heart Failure in a Dish: from iPSCs to Organoids
  • Emerging Discoveries in Myocardial Metabolism
  • The Future of Cardiac Fibrosis
  • Diabetes and Cardiomyopathies: Where are We Now and What is New?
  • Early Career Session:  Oh the Places You Can Go…With a PhD
  • Cardio Oncology: Protecting the Heart from Cancer Treatment
  • Cardiac Myofilaments: Mechanics and Regulations in Heart Failure
  • Pathways and Mechanisms of Apoptosis
  • Workshop: How to Effectively Interact with the NIH
  • Poster Session 2

  • Cardiac Arrhythmias: from Basic Mechanisms to Precision Medicine
  • Cardiac Inflammasome in Heart Failure
  • Rare Genetic Diseases of the Heart
  • Workshop: How to Talk to a Clinician from a Research Point of View
  • Outstanding Early Career Investigator Award Competition
  • New Frontiers in the Regulation of Cardiac Gene Expression
  • Promising Cardiovascular Research Abroad
  • Cross-talk Between Various Cell Types in Heart Failure
  • Top 5 Techniques to Advance the Cardiovascular Research
  • Poster Session 3

  • Aging and Cardiovascular Risk
  • Workshop: Social Media in Modern Cardiovascular Research
  • Machine Learning, Big Data and AI in Heart Disease
  • Development of Therapeutics for Heart Failure

About this Meeting

The 14th annual BCVS 2019 Scientific Sessions has become the premier conference for molecular cardiovascular biology and disease. Sponsored by the American Heart Association Basic Cardiovascular Sciences Council, the world’s leading organization of cardiovascular scientists, the conference attracts leading researchers in fields such as microRNAs, cardiac gene and cell therapy, cardiac development and most recently tissue engineering and iPS cells.

The planned agenda includes 15 fast-paced sessions during 3½ days, set in a forum that promotes the relaxed exchange and discussion of cutting edge research in molecular and translational cardiovascular biology and disease. The program includes a diversity of speakers representing the best cardiovascular scientists from around the world.

In addition, the symposium will be of great value to scientists and executives of pharmaceutical companies and biotechnology firms who are in the cardiovascular space.

Target Audience

  • Basic cardiovascular scientists
  • Molecular/cellular biologists
  • Physiologists
  • Translational investigators
  • Clinical trialists
  • Practicing cardiologists
  • Cardiovascular nurses and pharmacists

Learning Objectives

At the conclusion of the conference, participants will be able to:
  1. Describe current research into the underlying mechanisms of cardiac remodeling and its relevance to your own work.
  2. Discuss current research into cardiac fibrosis and its implications for your own work.
  3. Describe the most recent research related to the physiology and signaling pathways of cardiac myocytes and its implications for your work.
  1. Describe the potential role of and challenges involved in the use of big data analytics to guide cardiovascular research and patient care, and their implications for your work.
  2. Describe opportunities to bring a greater emphasis on translational research to your work.
  3. Describe emerging advances in the area of cardiovascular regenerative medicine, as well as current challenges.